Prior Recreational Cannabis Use Strongest Predictor of Willingness to Join Medical Cannabis Trials
Among 250 patients with inflammatory rheumatic diseases, 75% expressed interest in medical cannabis clinical trials, with prior recreational cannabis use being the strongest predictor of willingness to participate — raising important questions about selection bias in cannabinoid research.
Quick Facts
What This Study Found
Previous recreational cannabis use was the strongest predictor of interest in medical cannabis clinical trials (OR=1.89), followed by limitations in daily activities (OR=1.08) and biologic DMARD therapy (OR=1.43). Barriers included insufficient information (67%), fear of side effects (40%), and fear of dependence (31%).
Key Numbers
N=250; 67% female; 85% medication satisfaction; 35% interested in MC trials + 41% potentially interested; recreational use OR=1.89; daily activity limitations OR=1.08; bDMARD OR=1.43; barriers: information gap 67%, side effects 40%, dependence 31%
How They Did This
Survey of 250 inflammatory rheumatic disease patients (67% female) using an innovative chatbot app (Asepha) for patient-centered data collection, assessing sociodemographic, disease, treatment, and cannabis-related factors predicting clinical trial willingness.
Why This Research Matters
If recreational cannabis users self-select into medical cannabis trials, study results may not generalize to cannabis-naive patients — a critical methodological concern for the entire field of cannabinoid clinical research.
The Bigger Picture
This selection bias finding has implications beyond rheumatology — if cannabis-experienced individuals dominate clinical trials, the evidence base for medical cannabis may not reflect outcomes in typical patients encountering cannabis therapeutically for the first time.
What This Study Doesn't Tell Us
Single-center survey; convenience sample; self-reported recreational use; chatbot survey format may select tech-savvy patients; hypothetical willingness may not translate to actual enrollment; German regulatory context may not generalize.
Questions This Raises
- ?Should medical cannabis trials stratify by prior cannabis experience?
- ?How can researchers recruit cannabis-naive patients?
- ?Does prior cannabis experience change treatment expectations or responses?
Trust & Context
- Key Stat:
- Evidence Grade:
- Well-designed survey with innovative data collection and relevant clinical sample, though single-center and hypothetical willingness limit generalizability.
- Study Age:
- Published 2026; uses chatbot technology for data collection.
- Original Title:
- Recreational cannabis use is the driving factor for participation in medical cannabis trials in inflammatory rheumatic diseases.
- Published In:
- Phytomedicine : international journal of phytotherapy and phytopharmacology, 150, 157599 (2026)
- Authors:
- Jg, Richter, Beichert, A, Filla, T, Chehab, G, Sert, D, Aslandag, M, Distler, Jhw, Schneider, M, Frohne, I
- Database ID:
- RTHC-08365
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
Who volunteers for medical cannabis studies?
People who have already used recreational cannabis are nearly twice as likely to participate, which could skew research results since their experience, tolerance, and expectations differ from cannabis-naive patients.
Would rheumatology patients try medical cannabis?
About 75% of inflammatory rheumatic disease patients expressed some interest, even though 85% were satisfied with current treatment — but barriers include lack of information (67%), fear of side effects (40%), and fear of dependence (31%).
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-08365APA
Jg, Richter; Beichert, A; Filla, T; Chehab, G; Sert, D; Aslandag, M; Distler, Jhw; Schneider, M; Frohne, I. (2026). Recreational cannabis use is the driving factor for participation in medical cannabis trials in inflammatory rheumatic diseases.. Phytomedicine : international journal of phytotherapy and phytopharmacology, 150, 157599. https://doi.org/10.1016/j.phymed.2025.157599
MLA
Jg, Richter, et al. "Recreational cannabis use is the driving factor for participation in medical cannabis trials in inflammatory rheumatic diseases.." Phytomedicine : international journal of phytotherapy and phytopharmacology, 2026. https://doi.org/10.1016/j.phymed.2025.157599
RethinkTHC
RethinkTHC Research Database. "Recreational cannabis use is the driving factor for particip..." RTHC-08365. Retrieved from https://rethinkthc.com/research/jg-2026-recreational-cannabis-use-is
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.